BioSpace

BioSpace
  • 0,0 (0)
  • Ciências da Vida
  • Semanalmente

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

  1. -4 dias

    The next treatment-resistant depression paradigm

    In this episode of Denatured, you’ll hear from Hans Eriksson, chief medical officer at FundaMental Pharma and Steve Levine, chief patient officer at Compass Pathways. We explore why treatment-resistant depression remains so difficult to address, and how new approaches—from rapid-acting antidepressants to psychedelic therapy—may reshape the treatment paradigm. Host ⁠Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Hans Eriksson, Chief Medical Officer, FundaMental Pharma Steve Levine, Chief Patient Officer, Compass Pathways Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    The next treatment-resistant depression paradigm

  2. -5 dias

    Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms

    The industry has been abuzz since the weekend when talks of a potential mega-merger between Bristol Myers Squibb and AstraZeneca were reported. Meanwhile, Pfizer, Merck and others release second quarter earnings, with some disclosing pipeline discontinuations and cost-cutting measures. Finally, all eyes turn to the FDA in the wake of heated advisory committee meetings for Capricor Therapeutics and Replimune.

    Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms

  3. 30/07

    Life after the lead asset: Advancing an early-stage pipeline

    In this episode of Denatured presented by Arvinas, Jennifer Smith-Parker speaks to Arvinas President and CEO Randy Teel about the strategic discipline and leadership required to successfully refocus a company on an early-stage pipeline after a lead asset is outlicensed, discontinued or otherwise falls away — an inflection point many biotech and pharma companies face, but few navigate effectively. This episode is presented in partnership with Arvinas. Host Jennifer Smith-Parker, Director of Insights, BioSpace Guest Randy Teel, President and CEO, Arvinas

    Life after the lead asset: Advancing an early-stage pipeline

  4. 29/07

    Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more

    The FDA published briefing documents ahead of advisory committee meetings for Capricor Therapeutics’ Duchenne muscular dystrophy therapy and Replimune’s advanced melanoma drug indicating an uphill battle for the biotechs; GSK and AstraZeneca outlined ambitious plans in second quarter presentations; Sarepta tapped Michael Severino as its new CEO; and Amgen launched its official defense of Tavneos.

    Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more

  5. 23/07

    Nordic biotech’s next act: From fragmentation to global force

    In this episode of Denatured, you’ll hear from Ester Sklarsky, principal at Sound Bioventures and João Ribas, partner at Novo Holdings Seed Investments. In this episode, we explore the diverging trajectories of Nordic biotech and what it will take for the region, including Norway and Finland, to compete more cohesively on the global stage. Host Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Ester Sklarsky, Principal, Sound Bioventures João Ribas, Partner, Novo Holdings Seed Investments Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    Nordic biotech’s next act: From fragmentation to global force

  6. 22/07

    Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2

    Second quarter earnings continue to roll with Novartis and Roche reporting this week; Eli Lilly’s AtaiBeckley buy for up to $3.8 billion offers clear “validation” for the fledgling psychedelics space; more drama unfolds at FDA as the agency goes back and forth on its policy of publishing complete response letters in real-time; and IPO fever continues.

    Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2

  7. 16/07

    The future of pain relief: Exploring opioid alternatives

    In this episode of Denatured, you’ll hear from Lance Alstodt, chairman and CEO at Biorestorative Therapies, and Paul Mieyal, chief business officer at South Rampart Pharma. We explore why pain has remained such a difficult therapeutic area to tackle and one of the biggest unmet needs today, and how non-opioid mechanisms to regenerative therapies could reshape the future of treatment. Host Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Lance Alstodt, Chairman & CEO, BioRestorative Therapies Paul Mieyal, Chief Business Officer, South Rampart Pharma Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

    The future of pain relief: Exploring opioid alternatives

  8. 15/07

    Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup

    Biogen’s new data, presented at the Alzheimer's Association International Conference, supports a tau-focused approach to the intractable neurodegenerative disease; psychedelics are back in the news with more positive data from Compass Pathways and final guidance from the FDA; and the ATTR-CM space got a major shakeup with the late-stage failure of AstraZeneca and Ionis’ antisense therapeutic.

    Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup
Ver tudo (254)

Sobre

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.

Informação

  • Autoria
    BioSpace
  • Anos em atividade
    2023 - 2026
  • Episódios
    254
  • Classificação
    Para todos
  • Copyright
    © 2026 BioSpace
  • Site do programa
    BioSpace

Talvez também goste